Xcout Intel
Attgeno
Attgeno AB is a Swedish drug development company founded by researchers at the Karolinska Institute in Stockholm, focusing on medicines for conditions such as pulmonary hypertension.
Subscribe to see Attgeno’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Attgeno at a glance
Attgeno is a healthcare company headquartered in Sweden. Its most recent funding round closed in July 2022. Xcout tracks 5 named people at Attgeno, including Magnus Persson (Chairman of the Board).
Attgeno leadership
- Magnus PerssonChairman of the Board
- Christofer AddingBoard Member, CMO (and deputy CEO)
- Per AgvaldCEO, alternate Board Member (right of attendance)
- Anna TörnerBoard Member
- Johan SteinBoard Member
Attgeno funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| — | Undisclosed | 1 named | |
| PE | Undisclosed | 1 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Attgeno competitors
A few of Attgeno's closest competitors — see the full list of competitors and alternatives →
Salipro Biotech AB is a privately held biotechnology company headquartered in Stockholm, Sweden. The company is focused on unlocking challenging drug targets to advance drug discovery and develop next-generation therapeutics.
Airway Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel biologic therapies for respiratory and other diseases. The company is headquartered in Atlanta, Georgia.
GutCRINE is a biotech spinout from the University of Copenhagen headquartered in Holte, Denmark, focused on developing new drugs to prevent and treat common diseases.
Guard Therapeutics International AB is a clinical-stage Swedish biotechnology company that researches and develops novel therapies targeting kidney diseases with significant medical needs. Its drug candidates are based on the endogenous protein alpha-1-microglobulin (such as the GTX peptides and RMC-035).
AlzeCure Pharma is a Swedish clinical-stage biopharmaceutical company developing small-molecule therapies for neurodegenerative diseases, particularly Alzheimer’s disease and related cognitive disorders. Its programs target disease mechanisms and symptoms, serving patients with serious central nervous system conditions through potential prescription medicines.
Initiator Pharma is a clinical-stage biotechnology company that develops therapeutics targeting monoamine neurotransmitters for conditions such as erectile dysfunction, vulvodynia, and female sexual dysfunction. The company advances a pipeline of clinical and preclinical drug candidates, including its lead asset pudafensine, to address unmet medical needs in sexual medicine.
Get Attgeno's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about Attgeno? Suggest a correction
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Attgeno in Xcout Intel
- 5 named people with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access